Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Kusanationon Aug 18, 2020 6:42pm

439 Views

Post# 31425555

Reverse Split at AGM?

What do you think the chances are of a reverse split coming on the Aug.20 AGM call? I say this in light of them doing it in hopes to land on NASDAQ in the fall as they have stated that as being one of their goals in the past. I would really like to be back around the .70 range before the RS for our sake. Thoughts?

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide